Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL-Reference-Cited by-同舟云学术

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

Published:2017-06-29 Issue:26 Volume:129 Page:3419-3427
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Ding Wei¹,LaPlant Betsy R.²,Call Timothy G.¹,Parikh Sameer A.¹,Leis Jose F.³,He Rong⁴,Shanafelt Tait D.¹,Sinha Sutapa¹,Le-Rademacher Jennifer²,Feldman Andrew L.⁴,Habermann Thomas M.¹,Witzig Thomas E.¹,Wiseman Gregory A.⁵,Lin Yi¹,Asmus Erik²,Nowakowski Grzegorz S.¹,Conte Michael J.¹,Bowen Deborah A.¹,Aitken Casey N.¹,Van Dyke Daniel L.⁶,Greipp Patricia T.⁶,Liu Xin⁷,Wu Xiaosheng¹,Zhang Henan¹,Secreto Charla R.¹,Tian Shulan²,Braggio Esteban³,Wellik Linda E.¹,Micallef Ivana¹,Viswanatha David S.⁴,Yan Huihuang²,Chanan-Khan Asher A.⁸,Kay Neil E.¹,Dong Haidong⁷,Ansell Stephen M.¹

Affiliation:

1. Division of Hematology and

2. Department of Health Science Research, Mayo Clinic, Rochester, MN;

3. Department of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ;

4. Division of Hematopathology,

5. Department of Radiology,

6. Department of Laboratory Medicine and Pathology, and

7. Department of Immunology, Mayo Clinic, Rochester, MN; and

8. Division of Hematology, Mayo Clinic, Jacksonville, FL

Abstract

Key Points Pembrolizumab was first shown to be clinically active in CLL patients with RT. PD-1 and PD-L1 expression in tumor microenvironment are promising biomarkers to select RT patients for PD-1 blockade.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/129/26/3419/1401041/blood765685.pdf

Reference40 articles.

1. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib;Byrd;Blood,2015

2. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia;Byrd;N Engl J Med,2013

3. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia;Furman;N Engl J Med,2014

4. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia;Roberts;N Engl J Med,2016

5. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia;Maddocks;JAMA Oncol,2015

Cited by 349 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Iparomlimab, an Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors: A Phase 1c Study;Advances in Therapy;2024-09-14

2. Advances in the understanding of molecular genetics and therapy of Richter transformation in chronic lymphocytic leukemia;Leukemia & Lymphoma;2024-09-02

3. Targeting chronic lymphocytic leukemia with B‐cell activating factor receptor CAR T cells;MedComm;2024-09

4. Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial;The Lancet Oncology;2024-09

5. TIGIT: Will it be the next star therapeutic target like PD-1 in hematological malignancies?;Critical Reviews in Oncology/Hematology;2024-09